To assess, to control, to exclude: Effects of biobehavioral factors on circulating inflammatory markers

Brain, Behavior, and Immunity

Volumn 23, Issue 7, 2009, Pages 887-897

  O'Connor, Mary Frances ^a   Bower, Julie E ^a,b   Cho, Hyong Jin ^a   Creswell, J David ^c   Dimitrov, Stoyan ^a   Hamby, Mary E ^a   Hoyt, Michael A ^b   Martin, Jennifer L ^b   Robles, Theodore F ^b   Sloan, Erica K ^a   Thomas, KaMala S ^a   Irwin, Michael R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

Biobehavioral; Body mass index; Exclusion criteria; Exercise; Inflammation; Interleukin; SES

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CAFFEINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COFFEE; DEPRESSION; DIETARY INTAKE; DOSE RESPONSE; DRUG MECHANISM; DRUG RESPONSE; ETHNIC DIFFERENCE; EXERCISE; HEALTH BEHAVIOR; HORMONE ACTION; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR DEPRESSION; MEDLINE; OBESITY; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SLEEP DISORDER; SMOKING; SOCIAL PSYCHOLOGY; SOCIAL STATUS; STANDARDIZATION;

ANTICHOLESTEREMIC AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BODY MASS INDEX; DIET; EPIDEMIOLOGIC FACTORS; EXERCISE; HUMANS; INFLAMMATION; INTERLEUKINS; PATIENT SELECTION; PHYSICAL FITNESS; RESEARCH DESIGN; RISK FACTORS; RISK-TAKING; SMOKING; SOCIAL CLASS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349112063     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2009.04.005     Document Type: Article

References (175)

1. Abrahamsen B., Bonnevie-Nielsen V., Ebbesen E.N., Gram J., and Beck-Nielsen H. Cytokines and bone loss in a 5-year longitudinal study-hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis prevention study. J Bone Miner Res. 15 (2000) 1545-1554
2. Abrahamsen B., Stilgren L.S., Rettmer E., Bonnevie-Nielsen V., and Beck-Nielsen H. Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. Calcif. Tissue Int. 72 (2003) 18-23
3. Abramson J.L., Weintraub W.S., and Vaccarino V. Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 39 (2002) 197-202
4. Albert M.A., Glynn R.J., and Ridker P.M. Alcohol consumption and plasma concentration of C-reactive protein. Circulation 107 (2003) 443-447
5. Al-Harthi L., Wright D.J., Anderson D., Cohen M., Matity Ahu D., Cohn J., Cu-Unvin S., Burns D., Reichelderfer P., Lewis S., Beckner S., Kovacs A., and Landay A. The impact of the ovulatory cycle on cytokine production: evaluation of systemic, cervicovaginal, and salivary compartments. J. Interferon Cytokine Res. 20 (2000) 719-724
6. Alley D.E., Seeman T.E., Ki Kim J., Karlamangla A., Hu P., and Crimmins E.M. Socioeconomic status and C-reactive protein levels in the US population: NHANES IV. Brain Behav. Immun. 20 (2006) 498-504
7. Anand I.S., Latini R., Florea V.G., Kuskowski M.A., Rector T., Masson S., Signorini S., Mocarelli P., Hester A., Glazer R., and Cohn J.N. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112 (2005) 1428-1434
8. Anand S.S., Razak F., Yi Q., Davis B., Jacobs R., Vuksan V., Lonn E., Teo K., McQueen M., and Yusuf S. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1509-1515
9. Azar R.R., Klayme S., Germanos M., Kassab R., Tawm S., and Aboujaoudé S. Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. Am. J. Cardiol. 92 (2003) 236-239
10. Babyak M.A. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom. Med. 66 (2004) 411-421
11. Basterzi A.D., Aydemir C., Kisa C., Aksaray S., Tuzer V., Yazici K., and Goka E. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum. Psychopharmacol. 20 (2005) 473-476
12. Bazzano L.A., He J., Muntner P., Vupputuri S., and Whelton P.K. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann. Intern. Med. 138 (2003) 891-897
13. Berg A.H., and Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96 (2005) 939-949
14. Bermudez E.A., Rifai N., Buring J.E., Manson J.E., and Ridker P.M. Relation between markers of systemic vascular inflammation and smoking in women. Am. J. Cardiol. 89 (2002) 1117
15. Berrahmoune H., Lamont J.V., Herbeth B., FitzGerald P.S., and Visvikis-Siest S. Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: results from the STANISLAS cohort. Clin. Chem. 52 (2006) 504-510
16. Bo S., Gentile L., Ciccone G., Baldi C., Benini L., Dusio F., Lucia C., Forastiere G., Nuti C., Cassader M., and Pagano G.F. The metabolic syndrome and high C-reactive protein: prevalence and differences by sex in a southern-European population-based cohort. Diabetes Metab. Res. Rev. 21 (2005) 515-524
17. Bonita J.S., Mandarano M., Shuta D., and Vinson J. Coffee and cardiovascular disease: in vitro, cellular, animal, and human studies. Pharmacol. Res. 55 (2007) 187-198
18. Braveman P.A., Cubbin C., Egerter S., Chideya S., Marchi K.S., Metzler M., and Posner S. Socioeconomic status in health research: one size does not fit all. JAMA 294 (2005) 2879-2888
19. Bruunsgaard H., Skinhoj P., Pedersen A.N., Schroll M., and Pedersen B.K. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin. Exp. Immunol. 121 (2000) 255-260
20. Burgos I., Richter L., Klein T., Fiebich B., Feige B., Lieb K., Voderholzer U., and Riemann D. Increased nocturnal interleukin-6 excretion in patients with primary insomnia: a pilot study. Brain Behav. Immun. 20 (2006) 246-253
21. Castle S.C., Uyemura K., and Makinodan T. The SENIEUR Protocol after 16 years: a need for a paradigm shift?. Mech. Ageing Dev. 122 (2001) 127-130
22. Cullup H., Middleton P.G., Duggan G., Conn J.S., and Dickinson A.M. Environmental factors and not genotype influence the plasma level of interleukin-1 receptor antagonist in normal individuals. Clin. Exp. Immunol. 137 (2004) 351-358
23. Dandona P., Aljada A., and Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 25 (2004) 4-7
24. Danner M., Kasl S.V., Abramson J.L., and Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom. Med. 65 (2003) 347-356
25. De Bacquer D., Clays E., Delanghe J., and De Backer G. Epidemiological evidence for an association between habitual tea consumption and markers of chronic inflammation. Atherosclerosis 189 (2006) 428-435
26. Di Napoli M., and Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 34 (2003) 2922-2929
27. Dimitrov S., Lange T., Nohroudi K., and Born J. Number and function of circulating human antigen presenting cells regulated by sleep. Sleep 30 (2007) 401-411
28. Dotsenko O., Chaturvedi N., Thom S.A., Wright A.R., Mayet J., Shore A., Schalkwijk C., and Hughes A.D. Platelet and leukocyte activation, atherosclerosis and inflammation in European and South Asian men. J. Thromb. Haemost. 5 (2007) 2036-2042
29. Eilertsen A.L., Hoibraaten E., Os I., Andersen T.O., Sandvik L., and Sandset P.M. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 52 (2005) 111-118
30. Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R., and Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J. Am. Med. Assoc. 289 (2003) 1799-1804
31. Estruch R., Sacanella E., Badia E., Antúnez E., Nicolás J.M., Fernández-Solá J., Rotilio D., de Gaetano G., Rubin E., and Urbano-Márquez A. Different effects of red wine and gin consumption on inflammatory biomarkers of atherosclerosis: a prospective randomized crossover trial: effects of wine on inflammatory markers. Atherosclerosis 175 (2004) 117
32. Feldman M., Jialal I., Devaraj S., and Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J. Am. Coll. Cardiol. 37 (2001) 2036-2041
33. Fernandez-Real J.M., Broch M., Vendrell J., and Ricart W. Smoking, fat mass and activation of the tumor necrosis factor-[alpha] pathway. Int. J. Obes. Relat. Metab. Disord. 27 (2003) 1552
34. Ferrucci L., Corsi A., Lauretani F., Bandinelli S., Bartali B., Taub D.D., Guralnik J.M., and Longo D.L. The origins of age-related proinflammatory state. Blood 105 (2005) 2294-2299
35. Ferrucci L., Harris T.B., Guralnik J.M., Tracy R.P., Corti M.C., Cohen H.J., Penninx B., Pahor M., Wallace R., and Havlik R.J. Serum IL-6 level and the development of disability in older persons. J. Am. Geriatr. Soc. 47 (1999) 639-646
36. Fields L.E., Burt V.L., Cutler J.A., Hughes J., Roccella E.J., and Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 44 (2004) 398-404
37. Fishman J.R., Wick J.G., and Koenig B.A. The use of "Sex" and "Gender" to Define and Characterize Meaningful Differences Between Men and Women. Agenda for Research on Women's Health for the 21st Century (1999), NIH Publication, Bethesda, MD pp. 15-19
38. Fontana L., Meyer T.E., Klein S., and Holloszy J.O. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc. Natl Acad. Sci. USA 101 (2004) 6659-6663
39. Forouhi N.G., and Sattar N. CVD risk factors and ethnicity-a homogeneous relationship?. Atheroscler. Suppl. 7 (2006) 11-19
40. Forouhi N.G., Sattar N., and McKeigue P.M. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int. J. Obes. Relat. Metab. Disord. 25 (2001) 1327-1331
41. Frey D.J., Fleshner M., and Wright Jr. K.P. The effects of 40 h of total sleep deprivation on inflammatory markers in healthy young adults. Brain Behav. Immun. 21 (2007) 1050-1057
42. Frohlich M., Sund M., Lowel H., Imhof A., Hoffmeister A., and Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men: results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur. Heart J. 24 (2003) 1365-1372
43. Gage J.R., Fonarow G., Hamilton M., Widawski M., Mart¡nez-Maza O., and Vredevoe D.L. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation 11 (2004) 173-180
44. Gimeno D., Brunner E.J., Lowe G.D.O., Rumley A., Marmot M.G., and Ferrie J.E. Adult socioeconomic position, C-reactive protein and interleukin-6 in the Whitehall II prospective study. Eur. J. Epidemiol. 22 (2007) 675-683
45. Giraldo E., Hinchado M.D., Garcia J.J., and Ortega E. Influence of gender and oral contraceptives intake on innate and inflammatory response. Role of neuroendocrine factors. Mol. Cell. Biochem. 313 (2008) 147-153
46. Gu Q., Paulose-Ram R., Dillon C., and Burt V. Antihypertensive medication use among US adults with hypertension. Circulation 113 (2006) 213-221
47. Haack M., Sanchez E., and Mullington J.M. Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. Sleep 30 (2007) 1145-1152
48. Haddy N., Sass C., Maumus S., Marie B., Droesch S., Siest G., Lambert D., and Visvikis S. Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. Eur. J. Hum. Genet. 13 (2005) 109-117
49. Hamer M. The relative influences of fitness and fatness on inflammatory factors. Prev. Med. 44 (2007) 3-11
50. Hamer M., Williams E.D., Vuononvirta R., Gibson E.L., and Steptoe A. Association between coffee consumption and markers of inflammation and cardiovascular function during mental stress. J. Hypertens. 24 (2006) 2191-2197
51. Hauner H., Bender M., Haastert B., and Hube F. Plasma concentrations of soluble TNF-alpha receptors in obese subjects. Int. J. Obes. Relat. Metab. Disord. 22 (1998) 1239-1243
52. Heilbronn L.K., Noakes M., and Clifton P.M. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 968-970
53. Helmersson J., Larsson A., Vessby B., and Basu S. Active smoking and a history of smoking are associated with enhanced prostaglandin F2[alpha], interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis 181 (2005) 201
54. Hernández M.E., Mendieta D., Martínez-Fong D., Loría F., Moreno J., Estrada I., Bojalil R., and Pavón L. Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. Eur. Neuropsychopharmacol. 18 (2008) 917-924
55. Himmerich H., Fulda S., Linseisen J., Seiler H., Wolfram G., Himmerich S., Gedrich K., and Pollmacher T. TNF-alpha, soluble TNF receptor and interleukin-6 plasma levels in the general population. Eur. Cytokine Netw. 17 (2006) 196-201
56. Hinze-Selch D., Schuld A., Kraus T., Kuhn M., Uhr M., Haack M., and Pollmacher T. Effects of antidepressants on weight and on plasma levels of leptin, TNF-α and soluble TNF receptors: a longitudinal study in patients treated with amitryptyline or paroxetine. Neuropsychopharmacology 23 (2000) 13-19
57. Ho R.C., Davy K.P., Hickey M.S., and Melby C.L. Circulating tumor necrosis factor alpha is higher in non-obese, non-diabetic Mexican Americans compared to non-Hispanic white adults. Cytokine 30 (2005) 14-21
58. Hu F.B., Rimm E., Smith-Warner S.A., Feskanich D., Stampfer M.J., Ascherio A., Sampson L., and Willett W.C. Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire. Am. J. Clin. Nutr. 69 (1999) 243-249
59. Hung J., Knuiman M.W., Divitini M.L., Davis T., and Beilby J.P. Prevalence and risk factor correlates of elevated C-reactive protein in an adult Australian population. Am. J. Cardiol. 101 (2008) 193-198
60. Ikonomidis I., Andreotti F., Economou E., Stefanadis C., Toutouzas P., and Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100 (1999) 793-798
61. Im J.-A., Kim S.-H., Lee J.-W., Shim J.-Y., Lee H.-R., and Lee D.-C. Association between hypoadiponectinemia and cardiovascular risk factors in nonobese healthy adults. Metabolism 55 (2006) 1546-1550
62. Imhof A., Woodward M., Doering A., Helbecque N., Loewel H., Amouyel P., Lowe G.D.O., and Koenig W. Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: results from three MONICA samples (Augsburg, Glasgow, Lille). Eur. Heart J. 25 (2004) 2092-2100
63. Irwin M. Psychoneuroimmunology of depression: clinical implications. Brain Behav. Immun. 16 (2002) 1-16
64. Irwin M.R., Wang M., Campomayor C.O., Collado-Hidalgo A., and Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch. Intern. Med. 166 (2006) 1756-1762
65. Jiang R., Jacobs Jr. D.R., Mayer-Davis E., Szklo M., Herrington D., Jenny N.S., Kronmal R., and Barr R.G. Nut and seed consumption and inflammatory markers in the multi-ethnic study of atherosclerosis. Am. J. Epidemiol. 163 (2006) 222-231
66. Jilma B., Dirnberger E., Loscher I., Rumplmayr A., Hildebrandt J., Eichler H.G., Kapiotis S., and Wagner O.F. Menstrual cycle-associated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-reactive protein. J. Lab. Clin. Med. 130 (1997) 69-75
67. Jousilahti P., Salomaa V., Rasi V., Vahtera E., and Palosuo T. Association of markers of systemic inflammation, C reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status. J. Epidemiol. Community Health 57 (2003) 730-733
68. Kelley-Hedgepeth A., Lloyd-Jones D.M., Colvin A., Matthews K.A., Johnston J., Sowers M.R., Sternfeld B., Pasternak R.C., and Chae C.U. Ethnic differences in C-reactive protein concentrations. Clin. Chem. 54 (2008) 1027-1037
69. Kern P.A., Ranganathan S., Li C., Wood L., and Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 280 (2001) E745-E751
70. Khera A., McGuire D.K., Murphy S.A., Stanek H.G., Das S.R., Vongpatanasin W., Wians Jr. F.H., Grundy S.M., and de Lemos J.A. Race and gender differences in C-reactive protein levels. J. Am. Coll. Cardiol. 46 (2005) 464-469
71. Kiecolt-Glaser J.K., and Glaser R. Methodological issues in behavioral immunology research with humans. Brain Behav. Immun. 2 (1988) 67-78
72. Kiecolt-Glaser J.K., Preacher K.J., MacCallum R.C., Atkinson C., Malarkey W.B., and Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc. Natl Acad. Sci. USA 100 (2003) 9090-9095
73. Kivimaki M., Lawlor D.A., Juonala M., Smith G.D., Elovainio M., Keltikangas-Jarvinen L., Vahtera J., Viikari J.S.A., and Raitakari O.T. Lifecourse socioeconomic position, C-reactive protein, and carotid intima-media thickness in young adults: the cardiovascular risk in Young Finns Study. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2197-2202
74. Kluft C., Leuven J.A., Helmerhorst F.M., and Krans H.M. Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vascul. Pharmacol. 39 (2002) 149-154
75. Koh K.K., Son J.W., Ahn J.Y., Jin D.K., Kim H.S., Kim D.S., Han S.H., Chung W.-J., Park G.S., and Shin E.K. Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study. Atheroscler. Suppl. 177 (2004) 147-153
76. Koster A., Bosma H., Penninx B.W.J.H., Newman A.B., Harris T.B., van Eijk J.T.M., Kempen G.I.J.M., Simonsick E.M., Johnson K.C., Rooks R.N., Ayonayon H.N., Rubin S.M., Kritchevsky S.B., and Health A.B.C.S. Association of inflammatory markers with socioeconomic status. J. Gerontol. A: Biol. Sci. Med. Sci. 61 (2006) 284-290
77. Kraemer H.C., Stice E., Kazdin A., Offord D., and Kupfer D. How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. Am. J. Psychiatry 158 (2001) 848-856
78. Krum H., Ashton E., Reid C., Kalff V., Rogers J., Amarena J., Singh B., and Tonkin A. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J. Card. Fail. 13 (2007) 1-7
79. Lacut K., Oger E., Le Gal G., Blouch M.T., Abgrall J.F., Kerlan V., Scarabin P.Y., and Mottier D. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb. Haemost. 90 (2003) 124-131
80. Lakoski S.G., Cushman M., Criqui M., Rundek T., Blumenthal R.S., D'Agostino Jr. R.B., and Herrington D.M. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am. Heart J. 152 (2006) 593-598
81. LaMonte M.J., Ainsworth B.E., and Durstine J.L. Influence of cardiorespiratory fitness on the association between C-reactive protein and metabolic syndrome prevalence in racially diverse women. J. Womens Health 14 (2005) 233-239
82. Lear S.A., Chen M.M., Birmingham C.L., and Frohlich J.J. The relationship between simple anthropometric indices and C-reactive protein: ethnic and gender differences. Metabolism 52 (2003) 1542-1546
83. Lee S.K., Lee H.S., Lee T.B., Kim D.H., Koo J.R., Kim Y.K., and Son B.K. The effects of antidepressant treatment on serum cytokines and nutritional status in hemodialysis patients. J. Korean Med. Sci. 19 (2004) 384-389
84. Leo R., DiLorenzo G., Tesauro M., Razzini C., Forleo G.B., Chiricolo G., Cola C., Zanasi M., Troisi A., Siracusano A., Lauro R., and Romeo F. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitors. J. Clin. Psychiatry 67 (2006) 1760-1766
85. Levitzky Y.S., Guo C.-Y., Rong J., Larson M.G., Walter R.E., Keaney Jr. J.F., Sutherland P.A., Vasan A., Lipinska I., Evans J.C., and Benjamin E.J. Relation of smoking status to a panel of inflammatory markers: the Framingham offspring. Atherosclerosis 201 (2008) 217
86. Ligthart G.H. The SENIEUR protocol after 16 years: the next step is to study the interaction of ageing and disease. Mech. Ageing Dev. 122 (2001) 136-140
87. Liukkonen T., Rasanen P., Ruokonen A., Laitinen J., Jokelainen J., Leinonen M., Meyer-Rochow V.B., and Timonen M. C-reactive protein levels and sleep disturbances: observations based on the Northern Finland 1966 Birth Cohort study. Psychosom. Med. 69 (2007) 756-761
88. López-Bermejo A., Hernández-Aguado I., Vera I.J., Recasens M., Esteve E., Casamitjana R., Ricart W., and Fernández-Real J.M. Sex-specific, independent associations of insulin resistance with erythrocyte sedimentation rate in apparently healthy subjects. Thromb. Haemost. 97 (2007) 240-244
89. Lopez-Garcia E., Schulze M.B., Fung T.T., Meigs J.B., Rifai N., Manson J.E., and Hu F.B. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am. J. Clin. Nutr. 80 (2004) 1029-1035
90. Lopez-Garcia E., Schulze M.B., Meigs J.B., Manson J.E., Rifai N., Stampfer M.J., Willett W.C., and Hu F.B. Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J. Nutr. 135 (2005) 562-566
91. Lopez-Garcia E., van Dam R.M., Qi L., and Hu F.B. Coffee consumption and markers of inflammation and endothelial dysfunction in healthy and diabetic women. Am. J. Clin. Nutr. 84 (2006) 888-893
92. Lubbock L.A., Goh A., Ali S., Ritchie J., and Whooley M.A. Relation of low socioeconomic status to C-reactive protein in patients with coronary heart disease (from the heart and soul study). Am. J. Cardiol. 96 (2005) 1506-1511
93. MacKinnon D.P., Fairchild A.J., and Fritz M.S. Mediation analysis. Annu. Rev. Psychol. 58 (2007) 593-614
94. Maes M., Meltzer H.Y., Bosmans E., Bergmans R., Vandoolaeghe E., Ranjan R., and Desnyder R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2, and transferring receptor in major depression. J. Affect. Disord. 34 (1995) 301-309
95. Marfella R., Esposito K., Siniscalchi M., Cacciapuoti F., Giugliano F., Labriola D., Ciotola M., Di Palo C., Misso L., and Giugliano D. Effect of weight loss on cardiac synchronization and proinflammatory cytokines in premenopausal obese women. Diabetes Care 27 (2004) 47-52
96. Matthews K.A., Sowers M.F., Derby C.A., Stein E., Miracle-McMahill H., Crawford S.L., and Pasternak R.C. Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN). Am. Heart J. 149 (2005) 1066-1073
97. McDade T.W., Hawkley L.C., and Cacioppo J.T. Psychosocial and behavioral predictors of inflammation in middle-aged and older adults: the Chicago health, aging, and social relations study. Psychosom. Med. 68 (2006) 376-381
98. Mendall M.A., Patel P., Asante M., Ballam L., Morris J., Strachan D.P., Camm A.J., and Northfield T.C. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 78 (1997) 273-277
99. Mendall M.A., Strachan D.P., Butland B.K., Ballam L., Morris J., Sweetnam P.M., and Elwood P.C. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur. Heart J. 21 (2000) 1584-1590
100. Meng Y.X., Ford E.S., Li C., Quarshie A., Al-Mahmoud A.M., Giles W., Gibbons G.H., and Strayhorn G. Association of C-reactive protein with surrogate measures of insulin resistance among nondiabetic US from National Health and Nutrition Examination Survey 1999-2002. Clin. Chem. 53 (2007) 2152-2159
101. Mills P.J., von Kanel R., Norman D., Natarajan L., Ziegler M.G., and Dimsdale J.E. Inflammation and sleep in healthy individuals. Sleep 30 (2007) 729-735
102. Mohamed-Ali V., Goodrick S., Rawesh A., Katz D.R., Miles J.M., Yudkin J.S., Klein S., and Coppack S.W. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 82 (1997) 4196-4200
103. Mohamed-Ali V., Pinkney J.H., and Coppack S.W. Adipose tissue as an endocrine and paracrine organ. Int. J. Obes. Relat. Metab. Disord. 22 (1998) 1145-1158
104. Muzzio M.L., Berg G., Zago V., Basilio F., Sanguinetti S., Lopez G., Brites F., Wikinski R., and Schreier L. Circulating small dense LDL, endothelial injuring factors and fibronectin in healthy postmenopausal women. Clin. Chim. Acta 381 (2007) 157-163
105. Nanri A., Moore M.A., and Kono S. Impact of C-reactive protein on disease risk and its relation to dietary factors. Asian Pac. J. Cancer Prev. 8 (2007) 167-177
106. Nazmi A., Oliveira I.O., and Victora C.G. Correlates of C-reactive protein levels in young adults: a population-based cohort study of 3827 subjects in Brazil. Braz. J. Med. Biol. Res. 41 (2008) 357-367
107. Nettleton J.A., Steffen L.M., Mayer-Davis E.J., Jenny N.S., Jiang R., Herrington D.M., and Jacobs Jr. D.R. Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA). Am. J. Clin. Nutr. 83 (2006) 1369-1379
108. Nicklas B.J., Ambrosius W., Messier S.P., Miller G.D., Penninx B.W., Loeser R.F., Palla S., Bleecker E., and Pahor M. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am. J. Clin. Nutr. 79 (2004) 544-551
109. Nicklas B.J., You T., and Pahor M. Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. Can. Med. Assoc. J. 172 (2005) 1199-1209
110. O'Brien S.M., Fitzgerald P., Scully P., Landers A., Scott L.V., and Dinan T.G. Impact of gender and menstrual cycle phase on plasma cytokine concentrations. Neuroimmunomodulation 14 (2007) 84-90
111. Owen N., Poulton T., Hay F.C., Mohamed-Ali V., and Steptoe A. Socioeconomic status, C-reactive protein, immune factors, and responses to acute mental stress. Brain Behav. Immun. 17 (2003) 286-295
112. Pai J.K., Hankinson S.E., Thadhani R., Rifai N., Pischon T., and Rimm E.B. Moderate alcohol consumption and lower levels of inflammatory markers in US men and women. Atherosclerosis 186 (2006) 113
113. Palmas W., Ma S., Psaty B., Goff D.C., Darwin C., and Barr R.G. Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis. Am. J. Hypertens. 20 (2007) 233-241
114. Panagiotakos D.B., Pitsavos C., Yannakoulia M., Chrysohoou C., and Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis 183 (2005) 308-315
115. Panagiotakos D.B., Pitsavos C.E., Chrysohoou C.A., Skoumas J., Toutouza M., Belegrinos D., Toutouzas P.K., and Stefanadis C. The association between educational status and risk factors related to cardiovascular disease in healthy individuals: the ATTICA study. Ann. Epidemiol. 14 (2004) 188-194
116. Park H.S., Park J.Y., and Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diab. Res. Clin. Pract. 69 (2005) 29-35
117. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., and Myers G.L. Markers of inflammation and cardiovascular disease application to clinical and public health practice. A statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation 107 (2003) 499-511
118. Petersen A.M., and Pedersen B.K. The anti-inflammatory effect of exercise. J. Appl. Physiol. 98 (2005) 1154-1162
119. Plaisance E.P., and Grandjean P.W. Physical activity and high-sensitivity C-reactive protein. Sports Med. 36 (2006) 443-458
120. Pollitt R.A., Kaufman J.S., Rose K.M., Diez-Roux A.V., Zeng D., and Heiss G. Early-life and adult socioeconomic status and inflammatory risk markers in adulthood. Eur. J. Epidemiol. 22 (2007) 55-66
121. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc. Drug Rev. 24 (2006) 33-50
122. Prescott E., Godtfredsen N., Osler M., Schnohr P., and Barefoot J. Social gradient in the metabolic syndrome not explained by psychosocial and behavioural factors: evidence from the Copenhagen City Heart Study. Eur. J. Cardiovasc. Prev. Rehabil. 14 (2007) 405-412
123. Punjabi N.M., and Beamer B.A. C-reactive protein is associated with sleep disordered breathing independent of adiposity. Sleep 30 (2007) 29-34
124. Ranheim T., and Halvorsen B. Coffee consumption and human health-beneficial or detrimental?-mechanisms for effects of coffee consumption on different risk factors for cardiovascular disease and type 2 diabetes mellitus. Mol. Nutr. Food Res. 49 (2005) 274-284
125. Rankin J.W., and Turpyn A.D. Low carbohydrate, high fat diet increases C-reactive protein during weight loss. J. Am. Coll. Nutr. 26 (2007) 163-169
126. Rathmann W., Haastert B., Giani G., Koenig W., Imhof A., Herder C., Holle R., and Mielck A. Is inflammation a causal chain between low socioeconomic status and type 2 diabetes? Results from the KORA Survey 2000. Eur. J. Epidemiol. 21 (2006) 55-60
127. Raum E., Gebhardt K., Buchner M., Schiltenwolf M., and Brenner H. Long-term and short-term alcohol consumption and levels of C-reactive protein. Int. J. Cardiol. 121 (2007) 224
128. Reuben D.B., Cheh A.I., Harris T.B., Ferrucci L., Rowe J.W., Tracy R.P., and Seeman T.E. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J. Am. Geriatr. Soc. 50 (2002) 638-644
129. Rexrode K.M., Pradhan A., Manson J.E., Buring J.E., and Ridker P.M. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann. Epidemiol. 13 (2003) 674-682
130. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., and Gotto A.M. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344 (2001) 1959-1965
131. Rosvall M., Engstrom G., Janzon L., Berglund G., and Hedblad B. The role of low grade inflammation as measured by C-reactive protein levels in the explanation of socioeconomic differences in carotid atherosclerosis. Eur. J. Public Health 17 (2007) 340-347
132. Sadeghi M., Daniel V., Naujokat C., Weimer R., and Opelz G. Strikingly higher interleukin (IL)-1α, IL-1β and soluble interleukin-1 receptor antagonist (sIL-1RA) but similar IL-2, sIL-2R, IL-3, IL-4, IL-6, sIL-6R, IL-10, tumour necrosis factor (TNF)-α, transforming growth factor (TGF)-β2 and interferon IFN-γ urine levels in healthy females compared to healthy males: protection against urinary tract injury?. Clin. Exp. Immunol. 142 (2005) 312-317
133. Salkeld B.D., MacAulay J.C., Ball R.W., and Cannon J.G. Modulation of body temperature, interleukin-6 and leptin by oral contraceptive use. Neuroimmunomodulation 9 (2001) 319-325
134. Saijo Y., Kiyota N., Kawasaki Y., Miyazaki Y., Kashimura J., Fukuda M., and Kishi R. Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. Diab. Obes. Metab. 6 (2004) 249-258
135. Segerstrom S.C., and Miller G.E. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychol. Bull. 130 (2004) 601-630
136. Sharma S.K., Mishra H.K., Sharma H., Goel A., Sreenivas V., Gulati V., and Tahir M. Obesity, and not obstructive sleep apnea, is responsible for increased serum hs-CRP levels in patients with sleep-disordered breathing in Delhi. Sleep Med. 9 (2008) 149-156
137. Shurin G.V., Yurkovetsky Z.R., Chatta G.S., Tourkova I.L., Shurin M.R., and Lokshin A.E. Dynamic alteration of soluble serum biomarkers in healthy aging. Cytokine 39 (2007) 123-129
138. Sierksma A., van der Gaag M.S., Kluft C., and Hendriks H.F. Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels: a randomized, diet-controlled intervention study. Eur. J. Clin. Nutr. 56 (2002) 1130-1136
139. Sluzewska A., Rybakowski J.K., Laciak M., Maciewicz A., Sobieska M., and Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. N. Y. Acad. Sci. 762 (1995) 474-476
140. Solheim S., Arnesen H., Eikvar L., Hurlen M., and Seljeflot I. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am. J. Cardiol. 92 (2003) 843-845
141. Souter I., Janzen C., Martinez-Maza O., Breen E.C., Stanczyk F., Chaudhuri G., and Nathan L. Serum levels of soluble vascular cell adhesion molecule-1 are decreased in women receiving oral contraceptives compared with normally menstruating women: implications in atherosclerosis. Fertil. Steril. 83 (2005) 1480-1488
142. Stagnitti M.N. Trends in Antidepressant Use by the U.S. Civilian Noninstitutionalized Population, 1997 and 2002. Statistical Brief #76 (2005), Agency for Healthcare Research and Quality, Rockville, MD
143. Steinberg J.G., Ba A., Bregeon F., Delliaux S., and Jammes Y. Cytokine and oxidative responses to maximal cycling exercise in sedentary subjects. Med. Sci. Sports Exerc. 39 (2007) 964-968
144. Steptoe A., Owen N., Kunz-Ebrecht S., and Mohamed-Ali V. Inflammatory cytokines, socioeconomic status, and acute stress responsivity. Brain Behav. Immun. 16 (2002) 774-784
145. Straub R.H., Hense H.W., Andus T., Scholmerich J., Riegger G.A., and Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J. Clin. Endocrinol. Metab. 85 (2000) 1340-1344
146. Taylor S.E., Repetti R.L., and Seeman T. Health psychology: what is an unhealthy environment and how does it get under the skin?. Annu. Rev. Psychol. 48 (1997) 411-447
147. Thorand B., Baumert J., Doring A., Herder C., Kolb H., Rathmann W., Giani G., and Koenig W. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 184 (2006) 216-224
148. Tomaszewski M., Charchar F.J., Crawford L., Zukowska-Sczechowska E., Grzeszczak W., Sattar N., and Dominiczak A.F. Serum C-reactive protein and lipids in ultra-Marathon runners. Am. J. Cardiol. 94 (2004) 125-126
149. Tsao C.W., Lin Y.S., Chen C.C., Bai C.H., and Wu S.R. Cytokines and serotonin transporter in patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 899-905
150. Tuglu C., Kara S.H., Caliyurt O., Vardar E., and Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 170 (2003) 429-433
151. van Rooijen M., Hansson L.O., Frostegard J., Silveira A., Hamsten A., and Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J. Thromb. Haemost. 4 (2006) 77-82
152. Vgontzas A.N., Papanicolaou D.A., Bixler E.O., Lotsikas A., Zachman K., Kales A., Prolo P., Wong M.L., Licinio J., Gold P.W., Hermida R.C., Mastorakos G., and Chrousos G.P. Circadian interleukin-6 secretion and quantity and depth of sleep. J. Clin. Endocrinol. Metab. 84 (1999) 2603-2607
153. Vgontzas A.N., Zoumakis E., Bixler E.O., Lin H.M., Follett H., Kales A., and Chrousos G.P. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J. Clin. Endocrinol. Metab. 89 (2004) 2119-2126
154. Vgontzas A.N., Zoumakis M., Bixler E.O., Lin H.M., Prolo P., Vela-Bueno A., Kales A., and Chrousos G.P. Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels: physiologic and therapeutic implications. J. Clin. Endocrinol. Metab. 88 (2003) 2087-2095
155. Vitale C., Cornoldi A., Gebara O., Silvestri A., Wajngarten M., Cerquetani E., Fini M., Ramires J.A., and Rosano G.M. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Menopause 12 (2005) 552-558
156. Volpato S., Guralnik J.M., Ferrucci L., Balfour J., Chaves P., Fried L.P., and Harris T.B. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation 103 (2001) 947-953
157. Volpato S., Pahor M., Ferrucci L., Simonsick E.M., Guralnik J.M., Kritchevsky S.B., Fellin R., and Harris T.B. Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitior-1 in well-functioning older adults: the health, aging, and body composition study. Circulation 109 (2004) 607-612
158. Walston J.D., Fallin M.D., Cushman M., Lange L., Psaty B., Jenny N., Browner W., Tracy R., Durda P., and Reiner A. IL-6 gene variation is associated with IL-6 and C-reactive protein levels but not cardiovascular outcomes in the Cardiovascular Health Study. Hum. Genet. 122 (2007) 485-494
159. Wang J.J., Tung T.H., Yin W.H., Huang C.M., Jen H.L., Wei J., and Young M.S. Effects of moderate alcohol consumption on inflammatory biomarkers. Acta Cardiol. 63 (2008) 65-72
160. Wannamethee S.G., Whincup P.H., Rumley A., and Lowe G.D. Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J. Thromb. Haemost. 5 (2007) 1637-1643
161. Welsh P., Woodward M., Rumley A., and Lowe G. Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study. Br. J. Haematol. 141 (2008) 852-861
162. Willis C., Morris J.M., Danis V., and Gallery E.D. Cytokine production by peripheral blood monocytes during the normal human ovulatory menstrual cycle. Hum. Reprod. 18 (2003) 1173-1178
163. Winkleby M.A., Jatulis D.E., Frank E., and Fortmann S.P. Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. Am. J. Public Health 82 (1992) 816-820
164. Worns M.A., Victor A., Galle P.R., and Hohler T. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels-a study in twins. Genes Immun. 7 (2006) 600-605
165. Wunder D.M., Yared M., Bersinger N.A., Widmer D., Kretschmer R., and Birkhauser M.H. Serum leptin and C-reactive protein levels in the physiological spontaneous menstrual cycle in reproductive age women. Eur. J. Endocrinol. 155 (2006) 137-142
166. Xydakis A.M., Case C.C., Jones P.H., Hoogeveen R.C., Liu M.Y., Smith E.O., Nelson K.W., and Ballantyne C.M. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J. Clin. Endocrinol. Metab. 89 (2004) 2697-2703
167. Yanbaeva D.G., Dentener M.A., Creutzberg E.C., Wesseling G., and Wouters E.F.M. Systemic effects of smoking. Chest 131 (2007) 1557-1566
168. Yasui T., Uemura H., Yamada M., Matsuzaki T., Tsuchiya N., Noguchi M., Yuzurihara M., Kase Y., and Irahara M. Associations of interleukin-6 with interleukin-1beta, interleukin-8 and macrophage inflammatory protein-1beta in midlife women. Cytokine 41 (2008) 302-306
169. You T., and Nicklas B.J. Chronic inflammation: role of adipose tissue and modulation by weight loss. Curr. Diab. Rev. 2 (2006) 29-37
170. Yu C.-M., Zhang Q., Lam L., Lin H., Kong S.-L., Chan W., Fung J.W.-H., Cheng K.K.K., Chan I.H.-S., Lee S.W.-L., Sanderson J.E., and Lam C.W.-K. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 93 (2007) 933-939
171. Zampelas A., Panagiotakos D.B., Pitsavos C., Chrysohoou C., and Stefanadis C. Associations between coffee consumption and inflammatory markers in healthy persons: the ATTICA study. Am. J. Clin. Nutr. 80 (2004) 862-867
172. Zegura B., Guzic-Salobir B., Sebestjen M., and Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 13 (2006) 643-650
173. Zheng H., Patel M., Hryniewicz K., and Katz S.D. Association of extended work shifts, vascular function, and inflammatory markers in internal medicine residents: a randomized crossover trial. J. Am. Med. Assoc. 296 (2006) 1049-1050
174. Ziccardi P., Nappo F., Giugliano G., Esposito K., Marfella R., Cioffi M., D'Andrea F., Molinari A.M., and Giugliano D. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105 (2002) 804-809
175. Zorrilla E.P., Luborsky L., McKay J.R., Rosenthal R., Houldin A., Tax A., McCorkle R., Seligman D.A., and Schmidt K. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun. 15 (2001) 199-226